COMMUNIQUÉS West-GlobeNewswire

RedHill Biopharma to Host Second Quarter 2018 Financial Results Conference Call on August 30, 2018
24/08/2018
TEL-AVIV, Israel and RALEIGH, N.C., Aug. 24, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily [...]
Key information relating to the preferential rights issue to be carried out by PCI Biotech Holding ASA
24/08/2018
Date on which the terms and conditions of the preferential rights issue were announced: 24 august 2018 Last day including right: 14 September 2018 Ex-date: 17 September 2018 Record Date: 18 September 2018 Date of [...]
PCI Biotech: Notice of Extraordinary General Meeting
24/08/2018
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, HONG KONG OR SOUTH AFRICA, OR ANY OTHER [...]
Registration of merger, de-listing of Oncology Venture from Spotlight Stock Market, last day of trading and record date for the merger
24/08/2018
Hoersholm, Denmark, August 24, 2018 - Medical Prognosis Institute A/S (now Oncology Venture A/S) (the " Company ") and Oncology Venture Sweden AB (" OV ") hereby announce, as part of the completion of the previously [...]
Xbrane Biopharma releases interim report for the second quarter of 2018
24/08/2018
Press release 2018-08-24 Xbrane Biopharma AB's (publ.) ("Xbrane") interim report for the second quarter of 2018 is now available on the Company's website, www.xbrane.com . Financial summary second quarter 2018 Revenues [...]
Shire plc: Rule 2.9 Announcement
24/08/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 24 August 2018 [...]
Shire Announces FDA Approval of TAKHZYRO™ (lanadelumab-flyo), a First-of-its-Kind mAb Preventive Treatment for Hereditary Angioedema
24/08/2018
Shire Announces FDA Approval of TAKHZYRO ™ (lanadelumab-flyo), a First-of-its-Kind mAb Preventive Treatment for Hereditary Angioedema - In the pivotal study, patients taking TAKHZYRO 300 mg every 2 weeks had an 87% [...]
Navamedic ASA: Q2 2018 results
24/08/2018
Oslo, August 24, 2018 - Navamedic ASA (OSE: NAVA) reported revenues of NOK 45.2 million in the second quarter of 2018, down from NOK 89.7 million in the same period in 2017, following the planned discontinuation of the [...]
PCI Biotech convenes an extraordinary general meeting to propose a fully underwritten Rights Issue of NOK 360 million
24/08/2018
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, HONG KONG OR SOUTH AFRICA, OR ANY OTHER [...]
Navamedic ASA: Q2 2018 results
24/08/2018
Oslo, August 24, 2018 - Navamedic ASA (OSE: NAVA) reported revenues of NOK 45.2 million in the second quarter of 2018, down from NOK 89.7 million in the same period in 2017, following the planned discontinuation of the [...]
Kiadis Pharma to announce Financial Results for the six months ended June 30, 2018
24/08/2018
Kiadis Pharma to announce Financial Results for the six months ended June 30, 2018 Amsterdam, The Netherlands, August 24, 2018 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: [...]
DiaMedica Issues Stock Option Grant
24/08/2018
MINNEAPOLIS, Aug. 23, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the " Company ") (TSX VENTURE:DMA) (OTCQB:DMCAF), today announces it has issued 600,000 stock options to new employees and advisors of the [...]
Shire Announces FDA Approval of TAKHZYRO™ (lanadelumab-flyo), a First-of-its-Kind mAb Preventive Treatment for Hereditary Angioedema
24/08/2018
Shire Announces FDA Approval of TAKHZYRO ™ (lanadelumab-flyo), a First-of-its-Kind mAb Preventive Treatment for Hereditary Angioedema - In the pivotal study, patients taking TAKHZYRO 300 mg every 2 weeks had an 87% [...]
Telix Pharmaceuticals, University of Melbourne and Peter Mac to Collaborate on Colorectal Cancer
24/08/2018
MELBOURNE, Australia, Aug. 24, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”) has today announced a research collaboration with the University of Melbourne to investigate the [...]
Advanced Proteome Therapeutics Announces Closing of First Tranche of a Non-Brokered Private Placement
23/08/2018
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“ APC ” or the “ [...]
Terry Bradshaw Encourages Patients to “Take the Pledge to Live Well” in New PSA about Rheumatic Disease
23/08/2018
Atlanta, Aug. 23, 2018 (GLOBE NEWSWIRE) -- This September, Sports Broadcaster Terry Bradshaw is teaming up once again with the American College of Rheumatology (ACR) to share important information about rheumatic [...]
Veloxis Increases Share Capital in Connection with Exercise of Warrants
23/08/2018
Company Release no. 15/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 23 August 2018 Veloxis Increases Share Capital in Connection with Exercise of Warrants Veloxis Pharmaceuticals A/S announces that the Company's [...]
Cerner and Duke Clinical Research Institute Collaborate on Cardiac Risk App
23/08/2018
App presents vitals and lab measurements for cardiac risk patients to facilitate dialogue and help improve health outcomes KANSAS CITY, Mo., Aug. 23, 2018 (GLOBE NEWSWIRE) -- Cerner, a global leader in health care [...]
Intellia Therapeutics Presents Progress in Lead In Vivo Program at Cold Spring Harbor Laboratory’s Fourth Meeting on Genome Engineering: The CRISPR-Cas Revolution
23/08/2018
Robust, dose-responsive liver editing and reduction of TTR protein shown in humanized mouse model Therapeutically relevant reduction of serum TTR protein correlating with liver editing achieved in non-human primates [...]

Pages